Plain-English translation of NCT05951101 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Zenith LAA Occlusion System, a small device designed to seal off a pouch-like area in the heart called the left atrial appendage. This pouch is where dangerous blood clots often form in people with a heart rhythm disorder called atrial fibrillation. By sealing it off with this device, the treatment aims to prevent strokes in patients who may not be able to take blood thinners safely.
People with atrial fibrillation have a much higher risk of stroke because irregular heartbeats allow blood to pool and clot. While blood-thinning medications are the standard treatment, some patients cannot safely take them due to allergies, kidney problems, or bleeding risks. This device offers a mechanical alternative to protect these vulnerable patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the Zenith LAA Occlusion System implant through a minimally invasive procedure — meaning the doctor guides the device through a small catheter rather than through open-heart surgery. You will need imaging tests (ultrasounds and/or CT scans) before and after the procedure to ensure proper placement. After implantation, you will return for scheduled follow-up visits and testing to monitor your safety and how well the device is working, and you will take antiplatelet or anticoagulant medications as prescribed.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Australia
New Zealand